Yadav, Kritika
Lim, Joline
Choo, Joan
Ow, Samuel Guan Wei
Wong, Andrea
Lee, Matilda
Chan, Ching Wan
Hartman, Mikael
Lim, Siew Eng
Ngoi, Natalie
Tang, Siau Wei
Ang, Yvonne
Chan, Gloria
Chong, Wan Qin
Tan, Hon Lyn
Tan, Sing Huang
Goh, Boon Cher
Lee, Soo Chin http://orcid.org/0000-0002-5835-6419
Clinical trials referenced in this document:
Documents that mention this clinical trial
Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer
https://doi.org/10.1007/s10549-021-06470-7
Funding for this research was provided by:
Singapore ministry of health’s national medical research council (Centre Grant (CG) Programme (CGAug16M005), Clinician Scientist Award (SI Category, C/CSASI/0004/2015))
Article History
Received: 16 August 2021
Accepted: 30 November 2021
First Online: 20 December 2021
Declarations
:
: SGWO served on advisory boards and had speaker’s engagement with Pfizer, Novartis, Eli Lilly, AstraZeneca and Roche, and has received support to attend conference/travel from Pfizer, Novartis and AstraZeneca. AW has served on advisory board of Pfizer and Astra Zeneca. NN has received honoraria from Astra Zeneca, Janssen, Thermofisher and support to attend conferences from Astra Zeneca, Eisai. WQC has received conference sponsorship by MSD (ASCO 2021). GBC has been on advisory boards of MSD, AstraZeneca and Novartis and served as consultant to Adagene. He has received research support from BMS, MSD, Adagene and Taiho and has stock ownership of Merus and Gilead Sciences. SCL served on advisory boards and had speaker’s engagement with Pfizer, Novartis, Eli Lilly, Astra Zeneca, Roche, and ACT genomics, received research grants/ grants to support clinical trials from Eisai, Taiho, Pfizer, and Karyopharm, and has received support to attend conference/travel from Amgen, Pfizer, Novartis, Roche and ACT Genomics.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the National Healthcare Group Domain Specific Ethics Review Board in 2016 (DSRB 2016/00327).
: Signed written informed consent was obtained from all individual participants included in the study.